Companies › ADARx Pharmaceuticals
5 active drug programs in 10 registered trials: 4 Phase 1, 4 Phase 2, 2 Phase 3; Genitourinary, Cardiovascular, Hematology, Ophthalmology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADX-324 siRNA duplex oligonucleotide targeting KLKB1 | KLKB1 | Phase 3 | Hereditary Angioedema; Hereditary Angioedema (HAE) | Nov 2027 |
| ADX-038 siRNA duplex oligonucleotide | – | Phase 2 | Immunoglobulin A Nephropathy (IgAN); IgAN; Geographic Atrophy Secondary to Age-related Macular Degeneration; Paroxysmal Nocturnal Hemoglobinuria (PNH) | Mar 2028 |
| Telitacicept fusion protein | – | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | Jul 2028 |
| ADX-626 siRNA duplex oligonucleotide | – | Phase 1 | Healthy Adult Participants | Jan 2027 |
| ADX-850 siRNA duplex oligonucleotide | – | Phase 1 | Hypertension | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07081503 | ADX-626 | Phase 1 | Healthy Adult Participants | Other | Jan 2027 |
| NCT06205628 | ADX-850 | Phase 1 | Hypertension | Cardiovascular | Mar 2027 |
| NCT06960213 | ADX-324 | Phase 3 | Hereditary Angioedema | Immunology | Nov 2027 |
| NCT05691361 | ADX-324 | Phase 1 | Hereditary Angioedema | Immunology | Dec 2027 |
| NCT05876312 | ADX-038 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hematology | Mar 2028 |
| NCT07522099 | ADX-038 | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | Genitourinary | Jul 2028 |
| NCT07522099 | Telitacicept | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | Genitourinary | Jul 2028 |
| NCT06989359 | ADX-038 | Phase 2 | IgAN | Genitourinary | Dec 2028 |
| NCT06990269 | ADX-038 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Ophthalmology | Feb 2030 |
| NCT07428499 | ADX-324 | Phase 3 | Hereditary Angioedema (HAE) | Immunology | Jun 2030 |
Press releases filed as 8-K in the last year:
Kyowa Kirin KalVista Pharmaceuticals BioCryst Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics
TBF Genie Tissulaire Vensica Therapeutics BioCryst Pharmaceuticals Herbarium Laboratorio Botanico Ltda YolTech Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.